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Abstract 
Background People with Multiple Sclerosis (PwMS) are at an increased risk of 
diseases associated with low levels of physical activity (PA). Deconditioning may 
lead to an acceleration in the development of secondary complications from MS, 
impairing physical function and exacerbating disease progression. Functional 
Electrical Stimulation (FES) Cycling may provide a suitable lower limb exercise 
intervention for PwMS with mobility impairment. The effects of FES cycling on 
cardiovascular, musculoskeletal and functional outcomes for PwMS with mobility 
impairment are yet to be investigated to date. 
 
Objective The objective of this review was to systematically examine the outcomes 
of PwMS with mobility impairment following FES cycling intervention. 
 
Methods A systematic search of four electronic databases (MEDLINE, Web of 
Science, CINAHL and PEDro) from their inception to 8th January 2019 was 
performed. Inclusion criteria was 1) include human participants with definite 
diagnosis of MS 2) participants had to be aged 18 years or older 3) include 
participants with mobility impairment (determined as an average participant EDSS ≥ 
6.0) 4) evaluate FES cycling as an intervention study. 
 
Results Initial searches found 1163 studies. 9 of which met the full inclusion criteria: 
5 pre-post studies with no control group, 2 randomised controlled trials (RCTs), 1 
retrospective study and 1 case study. Two studies had the same participant group 
and intervention but reported different outcomes. Outcome data was available for 
n=76 unique participants, with n=82 completing a FES cycling intervention. Of the 
n=4 papers with clear dropout rates, pooled dropout rate was 25.81%. Two papers 
reported non-significant improvements in aerobic capacity following a FES cycling 
intervention. Four papers reported no change in lower limb strength and two papers 
reported significant reductions in spasticity post training. Four studies failed to 
provide information regarding adverse events with the other studies reporting n=10 
adverse events across 36 participants.  
 
Conclusion Findings suggest FES cycle training may reduce CVD risk alongside 
trends for a reduction in spasticity post training, however the low quality of the 
literature precludes any definitive conclusions. FES cycle training appears to be well 
tolerated in PwMS with mobility impairment, with no serious adverse events. 
 
Keywords 
Multiple Sclerosis; Mobility Impairment; Functional Electrical Stimulation;  
Functional Electrical Stimulation Cycling; High EDSS 
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1. Introduction  
 
Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the Central 
Nervous System (CNS) and is characterised by inflammation and neurodegeneration 
of the myelin sheath, axons and grey and white matter [1–5]. MS presents as 
symptoms of fatigue and impairment of both autonomic and somatic systems which 
have a deleterious impact on walking performance (and other types of physical 
activity), overall health, quality of life and ability to complete activities of daily living 
(ADLs) [2,3].  
 
In line with these limitations, people with MS (PwMS) frequently fail to engage in the 
recommended amounts of moderate-to-vigorous physical activity (MVPA) necessary 
to accrue health benefits [4]. Moreover, studies of PwMS also report that they 
experience both real and perceived barriers to engaging in physical activity (PA), 
which when combined with reductions in physical function, may promote an inactive 
lifestyle resulting in physical deconditioning [5,6].  
 
The consequences of insufficient PA and deconditioning may be particularly 
problematic in this cohort. PwMS are not immune to the increased risk of 
cardiovascular disease (CVD) occurring as a result of low levels of PA [7–9]. Indeed, 
deaths from secondary chronic conditions such as hypertension, increased 
cholesterol and diabetes are common, and the mortality rate in PwMS is estimated 
as being between 1.7 to 3.5 times greater than that of the general population [10,11]. 
In addition, deconditioning may lead to an acceleration in the development of 
secondary complications from MS in an interdependent manner. Deconditioning has 
been suggested to impair physical function and exacerbate disease progression, 
resulting in further reductions in levels of PA, and an associated cycle of decline in 
health [5,12,13]. Indeed, disease progression has been significantly correlated to 
reductions in aerobic capacity, muscular strength and walking performance 
[7,12,14,15]. 
 
Disease progression in MS is monitored and assessed utilising the Expanded 
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Disability Status Scale (EDSS) [16]. The scale describes different levels of 
impairment and ranges from 0 to 10, with 0 representing no symptoms and 10 
representing death [16]. An EDSS score of 6.0 is an identifiable milestone on the 
scale, whereby the individual can walk a maximum of 100m without stopping, even 
with the support of a unilateral assistive device [17]. As EDSS increases, PwMS are 
likely to participate in reduced amount of PA in comparison to those with lower 
EDSS, thus PwMS of disability levels of EDSS ≥ 6.0 are less likely to meet MVPA 
guidelines and have a greater risk of experiencing CV comorbidities [18]. For 
example, vascular comorbidities have been significantly correlated to an increased 
risk of mobility impairment and speed of disability progression [19]. Furthermore, 
whilst there is evidence that exercise has a multitude of health benefits for PwMS 
[20–22], few intervention studies have evaluated the effects of PA in persons with 
greater levels of impairment (e.g. EDSS of 6.0 and above).  
 
Sensorimotor impairments in MS typically impact on the lower limbs, with up to 75% 
of PwMS experiencing a gait impairment [23]. This can make the use of upper body 
exercise appealing [24]. Whilst both upper body and lower body exercises may have 
the potential to elicit cardiovascular adaptions in PwMS, it is important to note that 
the peripheral adaptation and conditioning of the lower limbs remain vital for PwMS’s 
mobility and contribute to their ability to complete personal and instrumental ADLs 
[25]. Lower body function is of particular importance in enabling PwMS to remain 
independent since it supports the completion of personal ADLs such as self-care, 
transfer and locomotion [26].  
 
Functional Electrical Stimulation (FES) cycling is a suggested lower limb exercise 
intervention for individuals who have higher levels of impairment [27]. FES cycling 
can be used where individuals are unable to propel a cycle ergometer independently 
due to reduced physical function [27].  The intervention applies electrical stimulation 
to the lower limb muscles, which is appropriately timed to generate cyclical 
contractions to propel the cycle ergometer [28]. This intervention has reported to 
benefit other neurological conditions, such as persons with incomplete or complete 
spinal cord injury (SCI), including increased lower limb skeletal muscle mass, 
muscular strength, and endurance whilst also improving aerobic capacity, and 
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glucose metabolism  [27,29,30]. In PwMS, FES cycling may support higher exercise 
intensities, enabling greater engagement with the level of MVPA than would be 
otherwise possible with passive leg cycling; increasing the potential for 
cardiovascular conditioning [31].  This methodology therefore, may be a feasible 
option for reducing comorbid CVD risk. 
Over the last decade, FES cycling has attracted an increased number of 
investigations due to the potential benefit this intervention has for PwMS, both in 
terms of supporting their physical functioning, and reducing CVD risk. To date, the 
evidence remains unclear as to the efficacy of FES cycling to support PwMS in 
maintaining cardiorespiratory and musculoskeletal health, and preventing the 
development of further comorbidities. No systematic evaluation has been conducted 
in this group. Given that FES cycling is a more appropriate intervention for those with 
higher levels of mobility impairment, the aim of this review is to systematically 
examine cardiovascular, musculoskeletal and functional outcomes in PwMS with 
mobility impairment following a FES cycling intervention. 
 
 
 
2. Methodology 
2.1. Search Strategy 
This systematic review was conducted was in accordance with the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRIMSA) statement 
[32]. A comprehensive literature search was performed in order to examine the effect 
of FES cycling on cardiovascular, musculoskeletal and functional outcomes in 
PwMS. Four electronic databases (MEDLINE, Web of Science, CINAHL and PEDro) 
were searched from their inception to 8th January 2019. Search terms used were as 
follows: (“Multiple Sclerosis” OR “Progressive MS” OR “Relapsing Remitting MS”) 
AND (“NMES” OR “FES” OR “ESAC” OR “neuromuscular stimulation” OR “electrical 
stimulation” OR “stimulation-assisted cycl*” OR “assisted cycl*”). Table 1 provides an 
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example of the search strategy. Filters were applied so that only research articles 
and articles that were peer-reviewed would be retrieved.  
 
 
Table 1: Sample Search Strategy 
#1 “Multiple Sclerosis” OR “Progressive MS” OR “Relapsing Remitting 
MS” [all fields] 
#2 “NMES” OR “FES” OR “ESAC” OR “neuromuscular stimulation” OR 
“electrical stimulation” OR “stimulation-assisted cycl*” OR “assisted 
cycl*” [all fields] 
#3 #1 AND #2 
NMES = Neuromuscular Electrical Stimulation, FES = Functional Electrical 
Stimulation, ESAC = Electrical Stimulation-Assisted Cycling. 
2.2. Description of the Intervention 
FES cycling utilises a commercially available motorised ergometer (e.g. RT300, 
Restorative Therapies Inc, Baltimore, MD, USA), typically accessed from a seated 
position [29]. This enables the user to remain on their wheelchair, reducing the 
requirement for transferring [33]. Stimulation electrodes are placed on the skin, 
typically above the quadriceps, hamstrings and glutei and a bilateral current is 
delivered to the muscles providing timed and cyclical stimulation necessary to 
produce a cycling motion [28,34]. A target cadence is predetermined on the 
ergometer with suitable software amending the electrical stimulation and ergometer’s 
resistance based on muscle fibre recruitment and fatigability [30]. Where a 
participant has leg function, their individual volitional efforts will contribute to attaining 
the target cadence [33].   
 
2.3. Inclusion Criteria 
To be included in this review, the study had to (1) include human participants with 
definite diagnosis of MS (2) participants had to be aged 18 years and over (3) 
include participants with an average EDSS 6.0 or above, or an equivalent mobility 
impairment (4) evaluate FES cycling as an intervention study. Since the number of 
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qualifying studies was anticipated to be small, no restrictions were placed on the 
type of study included in this review, and all qualifying studies were included 
regardless of study quality. 
 
2.4. Study Selection 
 
Following searches of the relevant databases, results were imported into 
bibliographic software (Zotero: V 5.0.60, Fairfax, VA, USA). Subsequently, articles 
were screened to remove duplicates. Two authors (JS and NS) independently 
conducted a literature search and screened the title and abstracts of relevant papers 
to remove studies which clearly did not meet the inclusion criteria. Where it was not 
clear in the title or abstract if the study was suitable for inclusion, the full text was 
read. Using the inclusion criteria, both authors independently generated a list of 
eligible studies. 
 
2.5. Data Extraction 
 
In addition to bibliographic data, the following information was extracted from each 
article by JS and verified by NS: (i) participant data (ii) intervention protocols (iii) 
intervention outcomes. 
 
2.6. Study Quality Assessment 
Study quality was appraised using four different tools based on study type. The 
majority of studies were evaluated using the tools designed by the National Heart, 
Lung and Blood Institute (NHLBI), specifically cohort studies [35] and RCTs [36]. 
Case studies were evaluated using the tools developed by Murad et al. [37] and 
retrospective studies using the Newcastle-Ottawa Scale [38]. 
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3. Results 
 
Figure 1 denotes the literature search and screening process undertaken. The initial 
search found 1162 potential articles supplemented with 1 study from an external 
source; with 9 of these meeting the inclusion criteria. Of these, 5 were pre-post 
studies with no control group [33,39–42], two were Randomised Controlled Trials 
(RCTs) [43,44], one was a retrospective study [45] and one was a case study [46]. 
Two papers reported different outcomes on the same participant group following the 
same intervention [43,44]. As a result, there was a total of 9 papers which underwent 
quality assessment, however these 9 papers describe 8 different interventions. For 
clarity, the remainder of this review will refer to papers, not interventions.  
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Figure 1: PRISMA flow diagram of literature search and review process 
 
1162 identified through 
database searching 
1 additional record identified 
through other sources 
996 records after duplicates removed 
996 of records screened 987 records excluded based 
 on title and abstract 
9 full-text articles 
assessed for eligibility 
9 studies included in 
qualitative synthesis  
0 of full-text articles 
excluded, with reasons 
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Inclusion criteria of all papers equated to mean EDSS ≥ 6.0. 1, demographic data only given for those that completed the 
intervention; 2, demographic data not split by control and intervention; 3, demographic data only given for those for those with 
Study 
[Citation] 
Study Design n Drop Out 
Participant Characteristics MS Related Measures Anthropometric Measures 
Sex Age (Years) 
EDSS 
Range 
Mean EDSS 
Disease 
Duration 
(Years) 
Type of MS Height (cm) Body Mass (kg) 
Body Mass Index 
(kg m
-2
) 
Backus et al. 
[33] 
Pre-Post No 
Control 
14 NR F=7 M=7 55.28 ± 10.98 NR NR 15.29 ± 7.35 PP=2 SP=7 RR=5 NR 
Edwards et al. / 
 Pilutti et al. 
[43][44]
15
 
RCT 
CON=5, 
FES=6 
CON=1, 
FES=2 
CON: F=4, 
FES: F=3 M=1 
CON: 48.5 ± 7.7, 
FES: 57.3 ± 6.0 
5.5 - 6.5  
CON: 6.3 ± 0.9, 
FES: 6.3 ± 0.5 
CON: 20.8 ± 8.5, 
FES: 22.3 ± 5.3 
CON: P=2 RR=2,   
FES: P=2 RR=2 
CON: 160.5 ± 9.2, 
FES: 161.1 ± 10.4  
CON: 85.8 ± 46.0, 
FES: 70.6 ± 19.5 
CON: 32.1 ± 13.9, 
FES: 27.2 ± 7.4 
Fornusek & 
Hoang [39] 
Pre-Post No 
Control 
8 1 F=8 39 ± 14 6.5 - 8.5 7.3 ±  0.7 NR SP=8 NR 
Hammond et al. 
[45]
2
 
Retrospective 
CON=10, 
FES=30 
NR F=27 M=13 54.7  ± 12 2.5 - 7.5 6.0 ± 1.4 16.8  ± 12.7 PP=12 SP=14 RR=14 NR 
Krause et al. 
[46] 
Case Study 1 NR M=1 46 - 7.5 NR SP=1 NR 
Ratchford et al. 
[40] 
Pre-Post No 
Control 
5 1 F=2 M=3 
50 (median) 
(range 46 - 60) 
6.0 - 6.5 6.5 (median) 
13 (median) 
(range 6 - 21) 
PP=2 SP=3 NR 
Reynolds et al. 
[41]
3
 
Pre-Post No 
Control 
14 NR F=1 M=7 54.5 ± 13.9 NR NR 16.8 ± 6.9 PP=2 SP=4 RR=2 NR NR 24.7 ± 3.3 
Szecsi et al. 
[42]
4
 
Pre-Post No 
Control 
12 4 F=1 M=11 50.9 ± 6.9 4.0 - 8.0 6.5 ± 1.1 15.3 ± 8.2 P=8 NR 
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measurable mVO2; 4, EDSS unknown for n=1; 5; two papers appear to be same participants and same intervention and have been 
grouped to prevent double counting; F, female; M, male; PP, Primary Progressive; RR, Relapsing Remitting; SP, Secondary 
Progressive; P, Progressive; Con, Control Group; FES, FES Cycling Group; NR, Not Reported. Data are mean ± SD unless 
otherwise stated.  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
3.1. Demographic Information 
 
The mean participant EDSS in each study was ≥ 6.0. Of the 9 selected papers, four 
did not exclusively feature participants with EDSS ≥ 6.0 [42–45]. Two papers did not 
report participant EDSS however their inclusion criteria approximately equated to 
that of participants with mobility impairment and EDSS ≥ 6.0 [33,41]. The highest 
level of impairment reported in participants was EDSS 8.5 [39]. Six papers utilised 
participants with both progressive and relapsing remitting MS [33,40,41,43–45]. 
Three exclusively recruited participants with progressive MS [39,42,46]. One study 
only provided age range therefore from the other 8 papers with extractable data, the 
mean participant age was 50.77±10.21 years and disease duration 17.14±8.35 
years. Two papers, which reported on the same participants reported body height 
and mass [43,44]. Three papers reported BMI in kg/m2 [41,43,44].  
 
In three papers, data were only provided for participants who completed the FES 
cycling intervention [33,41,45]. The same three papers failed to identify the number 
of participants recruited and drop outs [33,41,45]. Whilst one of the remaining papers 
was a case study, the other 5 papers reported dropout rates [39,40,42–44]. Two of 
these papers failed to provide demographic data for participants who withdrew 
[43,44]. In the four remaining papers a total of 23 out of 31 participants who started 
the FES cycling protocol completed and 8 dropped out; resulting in a pooled dropout 
rate of 25.81% [39,40,42,43].  
 
One paper only provided demographic information for those participants where the 
main outcome, muscle oxygen consumption (mVO2), was successfully measured 
[41]. Resting and Peak Heart Rate (HR) was provided in one paper, however these 
were from baseline assessments and not measured pre and post intervention [39]. 
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Table 3: Summary of Papers’ Intervention Protocols 
Study 
[Citation] 
Study Design Apparatus 
Muscles 
Stimulated 
Target 
Cadenc
e (rpm) 
Stimulation 
Settings 
Session 
Duration 
(mins) 
Frequency 
Study 
Duration 
(weeks) 
Total 
Number of 
Sessions 
Total 
Training 
Volume 
(mins) 
Continuous 
Stimulation 
(C) /  
Intervals of 
Stimulation 
(I) 
Progressio
n 
Setting 
Supervised 
(Y/N) 
Notes 
Backus et 
al. [33] 
Pre-Post No 
Control 
RT300 
Quadriceps, 
Hamstrings & 
Gluteals 
35 - 50 
PW = 200 μs;  
F = 50 Hz 
30 3 x a week 4 12 360 C 
↑ 0.14 Nm 
Increments 
(if 3 
sessions 
for 30 mins 
continuousl
y) 
Clinical Y 
If participant was 
unable to cycling 
for 30-mins, the 
cycle entered a 
passive mode for 
remainder of 
session 
Edwards et 
al. / Pilutti 
et al. 
[43][44]
1
 
RCT RT300 
Quadriceps, 
Hamstrings & 
Gluteals 
40 - 50 
PW = 250 μs;  
F = 50 Hz 
10 → 30 3 x a week 24 72 1800 C 
↑10 min 
after 4 
weeks (until 
30 min 
reached) 
Clinical Y 
CON completed on 
same apparatus. 
Fornusek & 
Hoang [39] 
Pre-Post No 
Control 
Motomed Viva 
1.5 & Custom 
Muscle 
Stimulator 
Quadriceps, 
Hamstrings & 
Gluteals 
10 
PW = 300 μs;  
F = 35 Hz; 
Initial SA = 30 mA 
40 ≈ 1.8 x a week ≈ 10 18 720 C 
↑ SA at 
constant 
rate to 
reach 
predetermi
ned level at 
20 minutes. 
Then 20 
mins at SA 
Clinical Y 
Participants 
instructed not to 
push voluntarily 
during the training. 
Hammond 
et al. [45] 
Retrospective 
RT300, 
MotoMed FES 
Ergometer, 
Portable 
Neuromuscular 
Electrical 
Stimulation Units 
300PV & SWISS 
Stim among 
others 
NR NR NR ≥ 60  
≈ 4.4 hours 
total ABRT a 
month 
≈ 8 ≈ 16 ≈ 960 NR NR Clinical Y 
Part of wider ABRT 
program. The 
average prescribed 
12-month ABRT 
consisted of two 3-
hour sessions per 
week administered 
in two blocks of 4 
weeks each. 
Krause et 
al. [46] 
Case Study 
Constant Current 
8-channel 
Stimulator 
Quadriceps, 
Gluteals & 
Femoral 
Biceps 
NR SA: 30 → 90 mA ≥ 30 1 x a week 2 2 ≈ 60 I 
Stimulation 
increased 
with 
tolerance 
Clinical Y 
Short breaks of 3-5 
mins 
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47 
48 
49 
Ratchford 
et al. [40] 
Pre-Post No 
Control 
RT300 
Quadriceps, 
Hamstrings & 
Gluteals 
NR 
Initial PD = 250 ± 
25% μs;  
Initial F = 33 - 45 
Hz 
≥ 60  ≈ 3.8 x a week 24 NR ≈ 5472 NR NR Home N 
Asked to use at 
least 3 times per 
week for at least an 
hour per session  
Reynolds 
et al. [41] 
Pre-Post No 
Control 
RT300 
Quadriceps, 
Hamstrings & 
Gluteals 
40 - 50 NR 30 ≈ 3 x a week 4 - 5 12 360 C 
↑ 0.14 Nm 
Increments 
(if 3 
sessions 
for 30 mins 
continuousl
y) 
Clinical Y 
Stimulation 
gradually increased 
to cause cycling at 
50 rpm. If 
participant was 
unable to cycling 
for 30-mins, the 
cycle entered a 
passive mode for 
remainder of 
session 
Szecsi et 
al. [42] 
Pre-Post No 
Control 
Theravital Cycle 
Ergometer & 
Constant Current 
8-channel 
Stimulator 
Quadriceps & 
Hamstrings 
NR 
F = 20 Hz;  
Max SA = 127 mA,  
Constant PW = 300 
μs 
12 - 18 3 x a week 2 6 72 - 108 I NR Clinical Y 
n=11 received 
conventional 
physiotherapy 5 
times a week, and 
outpatient n=1 
attended 
conventional 
physiotherapy 
sessions twice a 
week. Highest 
cycling resistance 
was selected that 
would allow the 
subject to tolerate 
well 12–18 min of 
active ergometric 
pedalling (with and 
without 
stimulation), but at 
the same time not 
become too 
exhausted. 
 
 
 
1, two papers appear to be same participants and same intervention and have been grouped to prevent double counting; F, frequency; PW, pulse width; PD, 
phase duration; SA, stimulation amplitude; NR, not reported; ABRT, Activity Based Restorative Therapy; RT300, Restorative Therapies Inc, Baltimore, MD, 
USA; Motomed Viva 1.5, Reck Medixintechnik GmBH, Betzenweiller, Germany; Motomed FES Ergometer, Reck Medixintechnik GmBH, Betzenweiller, 
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Germany; Portable Neuromuscular Electrical Stimulation Units 300PV, Empi, St Paul, MN, USA; SWISS Stim, Valmed, Sion, Swizerland; Constant Current 8-
channel Stimulator, Krauth + Timmermann , Germany; Theravital, Medica-Medizintechnik Ltd, Hochdorf, Germany. 
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3.2. Protocols 
 
Intervention duration ranged between 2 and 24 weeks. Eight papers were completed 
under supervision in a clinical exercise setting [33,39,41–46] and the remaining 
paper was undertaken unsupervised at home [40]. Seven papers conducted 2/3 
sessions per week for a range of 2 – 24 weeks [33,39–44]. The other two papers 
were once every week for 2 weeks [46] or completed in two blocks of 4 weeks [45]. 
 
In two papers, the protocol was unclear [40,45]. The protocol of five papers was to 
cycle continuously for a minimum of 10 - 60 minutes utilising FES [33,39,41,43,44]. 
Of these, the protocol for four papers was to reach a point where a participant could 
complete 30 minutes of FES cycling at a target cadence of 35 – 50 rpm 
[33,41,43,44]. Two papers utilised periods of stimulation interspersed with periods of 
rest [42,46]. 
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Table 4: Summary of Papers’ Objective Outcome Measures 
Study [Citation] Outcome Measures Pre-Post Intervention 
Adverse 
Events 
Type of Adverse Events 
Reported 
Backus et al. [33] 
↑ Resistance or Time during FESC ↔ Power during FESC, Lower Limb Strength (Combined MMT of Bilateral HF, KF, KE and AD), 
Spasticity (MAS), Fatigue (MFIS), Pain (MOS PES), Mental Health (MHI), QOL (MSQLI) 
0 - 
Edwards et al. / 
Pilutti et al.  
[43] [44]
1
 
↔ T25FW, MSWS-12, 2MW, TUG, VO2peak, WRpeak, KE Strength, KF Strength, Leg FFM, Leg FM, Leg % Fat, Leg BMD, Cognition 
(SDMT), Fatigue (FSS, MFIS), Pain (SF-MPQ), QOL (MSIS-29) 
7  
(6 Min, 1 Mod) 
Min (n=6): Skin Irritation/Redness 
n=3, Non-Debilitating Fatigue n=2, 
Increased Muscle Spasticity n=1 
 
Mod (n=1): Fall Outside of Training 
Fornusek & 
Hoang [39] 
↑ Left and Right Thigh Circumference NR NR 
Hammond et al. 
[45] 
↑ Lower Extremity Motor (ISNCSCI) ↔ Upper Extremity Motor (ISNCSCI), Light Touch (ISNCSCI), Pin Prick (ISNCSCI) NR NR 
Krause et al. [46] ↓ Spasticity (MAS) NR NR 
Ratchford et al. 
[40] 
↑ GDNF, IFNγ, IL-8, MIP-1α, MCP-1↔ EDSS, 2MW, T25FW, 9HPT, PASAT, TUG, KE Strength, KF Strength, HE Strength, HF 
Strength, FD Strength, Lower Limb Sensation, Spasticity (LLSMS), Gait, QOL (SF-36), Mental Health (SCL-90), Other cytokines, 
chemokines and growth factors 
3  
(2 Min, 1 Mod) 
Min (n=2): Bowel Incontinence n=1, 
Increased Muscle Spasticity n=1 
 
Mod (n=1): Fall Outside of Training 
Reynolds et al. 
[41] 
↑ Resistance or Time during FESC, mVO2  0 - 
Szecsi et al. [42] 
↔ Power during FESC, Smoothness during FESC, 10MWT (ST & LT), KE Strength, KF Strength, Spasticity (MAS, LT) ↓ Spasticity 
(MAS; ST)  
NR NR 
 
↑, significant increase (p ≤ 0.05); ↔, no significant change; ↓, significant decrease (p ≤ 0.05); 1, two papers appear to be same participants and same 
intervention and have been grouped to prevent double counting; Min, minor adverse event; Mod, moderate adverse event; FESC, functional electrical 
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stimulation cycling; HE, hip extensor; HF, hip flexor; KF, knee flexor; KE, knee extensor; AD, ankle dorsiflexor; FD, foot dorsiflexor; MMT, manual muscle test; 
MAS, modified ashworth scale; MFIS, modified fatigue impact scale; SDMT, symbol digit modalities test; SF-MPQ, short-form McGill pain questionnaire; MOS 
PES, medical outcomes study pain effects scale; MHI, mental health inventory; QOL, quality of life; MSQLI, multiple sclerosis quality of life index; SF-36 = 
short-form 36; SCL-90, symptom checklist-90; FSS, fatigue severity scale; T25FW, timed 25-foot walk test; 2MW, 2-minute walk; MSWS-12, 12-item multiple 
sclerosis walking scale; TUG, timed up-and-go; FFM, fat-free mass; FM, fat mass; BMD, bone mineral density; MSIS-29, 29-item multiple sclerosis impact 
scale; ISNCSCI, international standards for neurological classification of spinal cord injury; 9HPT, 9-hole peg test; PASAT, paced auditory serial addition test; 
LLSMS, lower limb spasticity measurement system; GDNF, glial cell-derived neurotrophic factor; IFNγ, interferongamma; IL-8, interleukin-8; MIP-α, 
macrophage inflammatory protein-1 alpha; MCP-1, monocyte chemotactic protein-1; 10MWT, 10m Walk Test; ST, Short-Term; LT, Long-Term. 
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3.3. Cardiorespiratory Performance 
 
One paper investigated mVO2 and reported no improvement following a FES cycling 
intervention [41]. One paper measured peak aerobic capacity (VO2peak) across 
control and intervention groups and measured no change [43]. Peak work rate 
(WRpeak) was measured in one paper, with no improvement following the intervention 
[43]. Two papers measured power generation during FES cycling across the duration 
of the intervention, reporting no change [33,42]. In two papers, where participants 
could cycle continuously for 30 minutes, the resistance at which they could cycle 
significantly increased [33,41]. Conversely, in the same two papers, where 
participants were unable to cycle continuously for 30 minutes, active cycling time 
significantly increased [33,41]. 
3.4. Functional Performance  
 
Walking performance was measured in three papers in a variety of tests; 2-minute 
walk test (2MW) [40,43], timed 25-foot walk test (T25FW) [40,43], 10m Walk Test 
(10MWT) [42] and 12-item MS Walking Scale (MSWS-12) [43]. All three papers 
reported insignificant changes [40,42,43]. Timed Up-and-Go (TUG) performance was 
measured in two papers; with no change post FES cycling [40,43]. 
 
3.5. Musculoskeletal Outcomes 
 
Lower body strength was commonly measured in the Knee Extensors (KE), Knee 
Flexors (KF), Hip Extensors, Hip Flexors and/or Dorsiflexors or in combined tests 
[33,40,42,43]. Three papers found no improvement in either KE or KF strength 
[40,42,43]. Combined strength testing of the Hip Flexors, KE, KF & Dorsiflexors did 
not change [33]. One study, that observed a significant increase in thigh volume 
failed to measure changes in muscle mass or fat free mass in order to ascertain the 
cause of such increase [39]. 
 
The most frequently measured parameter was spasticity [33,39,40,42,46]. Three 
papers utilised the Modified Ashworth Scale (MAS) [33,42,46]. One study utilised the 
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Lower Limb Spasticity Measurement System (LLSMS) [40]. One study used self-
reporting [39]. Three papers reported a reduction in spasticity post FES cycling; two 
papers described significant improvements in spasticity directly post FES cycling 
[42,46] and one paper described self-evaluated measures on an unspecified time 
frame [39]. Four papers reported no longer term improvements when measures were 
taken on different days [33,40,42,46]. 
3.6. Psychological Outcomes 
 
Two papers evaluated mental health finding no change utilising the Mental Health 
Inventory (MHI) and Symptom Checklist-90 accordingly [33,40]. Quality of Life was 
measured in three papers with no significant change post FES cycling [33,40,44]. 
 
3.7. Adverse Events 
 
Four papers did not explicitly report any information regarding adverse events 
[39,42,45,46]. Of the five remaining papers, a total of 36 participants reported 10 
adverse events; none of which were described as serious [33,40,41,43,44]. Only two 
papers specifically discuss MS-related adverse events and in both cases, none were 
reported [33,41]. Two papers reported 8 minor events which included skin irritation, 
increased spasticity, bowel dysfunction and fatigue [40,43]. Two papers both 
reported a moderate adverse event which caused a participant to drop out; both of 
which were falls noted by researchers as unrelated to the intervention [40,43]. 
 
 
 
 
 
 
 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
Table 5: NHLBI Quality Assessment Tool for Before-After (Pre-Post) Studies With No Control Group 
 
Y, yes; N, no; UC, unclear; NR, not reported. 
Study [Citation] 
Research 
question 
clear? 
Participant 
eligibility 
criteria 
clear?  
Participants 
representative of 
clinical 
population of 
interest? 
Were all 
eligible 
participants 
enrolled?  
Was sample size 
sufficiently large to 
provide confidence 
in the findings? 
Was the 
intervention 
clearly 
described 
and delivered 
consistently?  
Outcome 
measures 
prespecified, 
clear, valid 
and reliable? 
Assessed 
consistently? 
Blinded 
assessment 
of 
outcomes? 
Loss to 
follow-up 
after 
baseline 
≤20% 
Did the 
statistical 
method examine 
changes pre and 
post 
intervention? p 
values 
provided? 
Outcome 
measures 
taken multiple 
times pre and 
post 
intervention? 
Backus et al. [33] Y Y Y Y UC Y Y N NR Y N 
Fornusek & Hoang 
[39] 
Y Y Y Y UC Y N N Y N N 
Ratchford et al. [40] Y Y Y Y N Y Y N Y N N 
Reynolds et al. [41] Y Y Y Y UC Y Y N NR Y N 
Szecsi et al. [42] Y Y Y Y UC Y Y N N Y N 
Study [Citation] 
Domain 
Selection Ascertainment Causality Reporting 
Patient represent whole experience of 
the investigator or is the selection 
method unclear to the extent that other 
patients with similar presentation may 
not have been reported? 
Exposure 
adequately 
ascertained? 
Outcome 
adequately 
ascertained? 
Other alternative causes 
that may explain the 
observation ruled out? 
Challenge/rechallenge 
phenomenon? 
Dose–
response 
effect? 
Follow-up long 
enough for 
outcomes to 
occur? 
Case described with 
sufficient details to allow 
other investigators to 
replicate the research or 
to allow practitioners 
make inferences related 
to their own practice? 
Krause et al. [46] UC Y Y N N N Y Y 
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 Table 6: Quality Assessment of Case Reports and Case Series 
 
Y, yes; N, no; UC, unclear. 
Table 7: NHLBI Quality Assessment for Controlled Intervention Studies 
Study 
[Citation] 
Study 
described 
as RCT? 
Method of 
randomisation 
adequate? 
Treatment 
allocation 
concealed? 
Study 
participants 
and providers 
blinded to 
treatment 
group 
assignment? 
Outcome 
assessors 
blinded to 
participants' 
group 
assignments? 
Groups 
similar at 
baseline on 
important 
characteris
tics that 
could affect 
outcomes? 
Drop out 
rate at 
endpoint 
≤20% or 
lower of 
number 
allocated to 
treatment? 
Differential 
drop-out 
rate at 
endpoint 
≤15% 
High 
adherence to 
intervention 
protocols for 
each 
treatment 
group? 
Were other 
interventions 
avoided or 
similar in the 
groups? 
Were 
outcomes 
assessed 
using valid 
and reliable 
measures, 
implemented 
consistently 
across all 
participants? 
Sample size 
sufficiently 
large to 
detect 
difference in 
main 
outcome 
between 
groups with 
≥80% power? 
Outcomes 
reported or 
subgroups 
analysed 
prespecified? 
All 
randomised 
participants 
analysed in 
group to 
which they 
were 
originally 
assigned? 
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Y, yes; N, no; NR, not reported; 1, two papers appear to be same participants and same intervention and have been grouped to prevent double counting. 
Table 8: Newcastle-Ottawa Quality Assessment Scale for Case Control Studies 
 
★, one star. 
Edwards et al. 
/ Pilutti et al. 
[43][44]
1
 
Y Y Y N Y Y N Y Y NR Y N Y N 
Study [Citation] 
Domain 
Selection Comparability Outcome 
Case Definition 
Adequate? 
Representativeness of cases 
Selection of 
controls 
Definition of 
controls 
Comparability of cases 
and controls on basis 
of design or analysis 
Ascertainment of 
exposure 
Same ascertainment 
for cases and controls 
Non-response rate 
Hammond et al. 
[45] 
★   ★     ★ ★   
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3.8. Study Quality 
 
The study quality assessment tools indicated that papers consistently had unclear or 
insufficient sample sizes to provide confidence in the findings. The largest sample 
size was that of a retrospective study, which contained 40 participants [45]. Of the 8 
other papers, sample size ranged from 1 to 14 [33,39–44,46]. Across all nine papers, 
82 participants were reported to complete a FES cycling intervention, but outcome 
data was only provided for 76 [33,39–46]. Only two papers had a blinded 
assessment of outcome measures [43,44]. Across the 7 papers with cohort study 
designs [33,39–44], only 2 reported a dropout rate ≤20% [39,40]. None of the papers 
included in this review recorded outcome measures multiple times following a FES 
cycling intervention [33,39–46]. 
4. Discussion 
 
The aim of this systematic review was to conduct a comprehensive literature search 
examining the effect of FES cycle training on cardiovascular, musculoskeletal and 
functional outcomes in PwMS and EDSS ≥ 6.0. The heterogeneity in outcome 
measures across the nine papers prevented a meta-analysis. The low quality of the 
literature base precludes any definitive conclusions regarding the efficacy of FES 
cycle training in improving cardiovascular health in PwMS and higher EDSS scores. 
In the present review, one of the main findings is that FES cycle training appears to 
be well tolerated in PwMS with mobility impairment, with no serious adverse events. 
 
4.1. Cardiorespiratory Performance 
Aerobic capacity is a strong indicator of cardiovascular fitness and associated CVD 
risk in PwMS [7]. CVD is of particular risk for PwMS, with papers demonstrating that 
PwMS are more likely to have CVD in comparison to healthy controls [5,47]. 
Although definitive data is lacking, it is plausible that those with the greatest level of 
mobility impairment are subject to an increased risk of CVD, with a significant 
correlation between disease progression and aerobic capacity [7,14]. Whilst aerobic 
training has been demonstrated to reduce this CVD in PwMS [48]; the majority of this 
work has been in those with EDSS < 6.0, whereas those with higher mobility 
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impairment (e.g. EDSS ≥ 6.0) have been poorly researched in the literature [48]. 
FES cycling has the potential to increase the dose of exercise attainable in PwMS 
with higher mobility impairment, and could therefore increase aerobic capacity and 
PA [31,49]. However, despite this potential, from the evidence of this review, the 
effectiveness of FES cycling in improving aerobic capacity is equivocal. Only two 
papers recorded valid objective measures of aerobic capacity [41,43]. One paper 
found a significant increase in peripheral oxygen consumption (mVO2) following 360 
minutes of FES cycle training across 4 weeks while the other study reported trends 
for improvement in VO2peak that fell short of statistical significance [38,42]. In both 
cases, the samples were small (n≤8) and the studies were underpowered, making it 
difficult to draw definitive conclusions.  
Walking tests are associated with aerobic capacity in PwMS [12]. In the present 
review, walking performance was the most frequently utilised functional test 
[40,42,43] however no papers reported any improvements. This apparent limited 
effectiveness may be due to the lack of specificity since walking performance is also 
reliant on balance and lower limb strength asymmetries [12]. Moreover, whether 
different doses of exercises would be more effective (e.g. longer duration or higher 
intensity) remain to be determined. Indeed, the high level of variability within the FES 
cycling interventions makes it difficult to attribute any changes to a specific protocol. 
While four of the nine papers had similar protocols [33,41,43,44], only two had 
matched training volumes and outcome measures in both papers had a high level of 
variability [33,39].  
 
 
4.2. Cardiovascular Risk Factors 
Obesity, typically measured utilising BMI, is a well-accepted and independent risk 
factor for CVD [50]. Given the increased risk of CVD in PwMS compared to the 
general population, it is surprising that only two papers provided BMI data [41,43]. 
One paper gave baseline measures for BMI [41]. The other paper provided more 
nuanced assessment of fat free mass, fat mass and bone density (measured utilising 
a bone densitometer) and reported no change following FES cycle training [43]. The 
overall poor reporting of BMI and small sample size in Edwards et al. [43] makes it 
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difficult to assess the role of FES cycle training in preventing obesity as a CVD risk 
factor.  
 
However, the accuracy of standard BMI thresholds for persons with lower limb 
impairment have been questioned since BMI does not distinguish between muscle 
and fat compartments [51]. Consequently, in persons with reduced lower limb 
muscle tone and bone density, BMI thresholds designed for able bodied persons 
may underestimate the risk of increased body fat [51]. Notably, in this regard FES 
cycling has been reported to improve body composition including increase in lean 
tissue in persons with SCI [52]. However, the potential of FES cycling to produce 
similar effects in PwMS is yet to be investigated. 
 
4.3. Spasticity 
Spasticity is a common and debilitating symptom for persons with MS [53,54]. In 
particular, this is important for PwMS since disease progression and duration are 
both strongly correlated with spasticity and reductions in mobility [54,55]. Alongside a 
reduction in mobility and associated independence, spasticity can also be a direct 
source of MS-related pain [56]. FES cycling has been suggested as a possible 
support mechanism for spasticity since it is associated with a reduction in spastic 
muscle tone in persons with SCI [58] but the degree to which this is the case with 
PwMS remains to be determined. 
 
Spasticity was the most commonly recorded measure, and FES cycle training 
appears to acutely  improve symptoms of spasticity but this does not appear to 
translate into medium term effects (defined as approximately 48 hours after training) 
[42,46]. No papers evaluated longer term effects of FES cycling and thus the effect 
of FES cycle training in reducing spasticity > 48 hours remains unclear. The MAS 
was the most frequently utilised measurement within this review and is commonly 
used to measure spasticity in persons with MS [55]. That being said, a number of 
limitations are reported with the MAS related to inter-rater reliability, sensitivity to 
change and insufficient guidelines regarding its use [52,54]. Future studies should 
look to use more robust measures of spasticity with less subjectivity. 
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4.4. Lower Limb Muscular Strength 
Lower Limb Muscular Strength is correlated to walking performance in PwMS and is 
important in enabling PwMS to complete personal and instrumental ADLs [26,57]. 
Clearly, one aim of FES cycling is to stimulate the musculature of the lower limbs 
thus aiming to increase strength, reduce the rate of decline and preserve function in 
the lower body; with the potential to support PwMS’s ability to maintain ADLs. 
Moreover when this lower limb function is lost, this in turn translates into greater 
loads being placed on the upper body and a higher risk of chronic upper body injury 
[58,59]. Four papers assessed this outcome, however no improvements in lower 
body muscular strength following FES cycle training were found within the present 
review [33,40,42,43].  
 
Clearly, cycling is generally considered to be aerobic in nature and may be 
considered to produce modest increases in muscular strength. Indeed, to elicit 
skeletal muscle hypertrophy in healthy populations using aerobic exercise, the 
optimum exercise intensity is suggested as a minimum of 70% HR reserve (HRR), 4 
times a week for 30 minutes [60]. Given that none of the papers included in this 
review had sufficient exercise volume to equate to this, nor was %HRR or %VO2peak 
set as a target within the interventions, it is perhaps not surprising that no changes in 
strength were noted. Moreover, FES cycling can be considered as a dynamic 
training modality with moderate speeds of muscle contraction. However, in all cases, 
strength was assessed isometrically using semi-quantitative [33,42], static [45] or 
isokinetic [43] methods. It is well established that changes in strength are specific to 
the speed and type of contraction used in training, and outcome measures should 
reflect the training mode [61]. Indeed, strong correlations only existed between 
isometric and dynamic strength using large forces, or explosive power as anticipated 
[62], which was not the case in the interventions used in the papers.  
Consequently, the conclusion that FES cycling does not improve strength in PwMS 
with EDSS ≥ 6.0 should be viewed with caution, and must be re-evaluated with more 
appropriate protocols, given the mismatch between training stimulus and outcome 
assessment. Evidence has shown that PwMS and mobility impairment can reach 
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higher %HRpeak during an acute bout of FES cycling in comparison to passive leg 
cycling (76.4%HRpeak vs 55.5%HRpeak) [31]. This supports the theory that FES cycling 
protocols have the potential to provide increases in strength. A further limitation is 
that of the papers in this review, only two interventions were longer than 10 weeks 
and in both cases, sample sizes were too small to make meaningful interpretations 
(n=4 completed in both cases) [40,43,44]. Another consideration for those papers 
that measured muscular strength, is that the majority had no control group. As 
disease progression is correlated to reductions in lower limb muscular strength, 
future research should look to determine if maintenance of muscular strength is 
clinically meaningful over time in comparison to controlled counterparts [12].  
 
4.5. Adverse Events & Adherence 
Accurate reporting of adverse events is particularly important in this group since 
there are few intervention papers evaluating the benefits of PA in persons with EDSS 
≥ 6.0 [20–22].  In general, previous studies have indicated exercise to be safe in 
PwMS, with one systematic review of RCT’s reporting no increased risk of relapse 
[63]. However, a notable limitation is that, in that review,  only one of the papers 
included participants with a mean EDSS ≥ 6.0 and none included participants with an 
EDSS > 6.5 [63]. One systematic review has reported on exercise interventions for 
PwMS and EDSS ≥ 6.0 but did not come to any meaningful conclusions regarding 
exercise safety, in part due to the small number of research papers evaluating this 
population [64]. This present review extends these findings, by identifying consistent, 
if limited evidence that FES cycle training in PwMS who have an EDSS ≥ 6.0 
appears to be well tolerated with no serious adverse events. Moreover, while there 
are clear differences in aetiology, this finding is in broad agreement with substantial 
evidence regarding the reported benefits of FES cycling and safety in persons with 
SCI [65].  
 
Whilst encouraging, it is important to note that reporting of adverse events was 
generally poor, making more detailed recommendations in PwMS and higher EDSS 
scores difficult. Moreover, PwMS and EDSS ≥ 6.0 are relatively poorly represented 
in the MS literature regarding exercise interventions, with little information in regards 
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to adherence to exercise interventions, and potential barriers to participation they 
experience. Future FES cycling studies should seek to explicitly provide adverse 
event data in this population. 
 
This review also found poor reporting of participant recruitment and dropout rates 
thus impacting on the conclusions which can be drawn regarding attrition. By only 
reporting the outcomes of those completing an intervention, investigators risk attrition 
bias which, hampers the understanding of exercise adherence and the capacity of 
this population to sustain FES cycling at prescribed training volumes [66]. 
Understanding exercise adherence and how to increase participation in persons with 
MS is an important area for future research [2]. 
 
4.6. Quality of the Literature 
 
Nine papers of varying study design were considered in this review. Most papers had 
small sample sizes that lacked justification, and therefore had underpowered 
statistical analysis. For example, the sample sizes across all the pre-post cohort 
studies were relatively small. Moreover, two papers attempted to overcome sample 
size limitations by calculating effect sizes for all insignificant outcomes [43,44]. While 
this is understandable, it is important that insignificant improvements aren’t assumed 
to be type 2 errors, as underpowered studies may also artificially inflate the effect 
size [67]. Studies must seek to increase their sample sizes or provide statistical 
justification for their sample size use if any meaningful conclusions regarding the 
effect of FES cycling in persons with MS are to be assessed. The only study to have 
sufficient sample size for statistical power was the retrospective paper by Hammond 
et al. [45]. However, in this case, participation allocation into either FES cycling or 
control groups was decided for clinical reasons, suggesting that finding may be 
affected by allocation bias [68].  
Of concern is the preponderance of subjective outcome measures in certain papers 
[39]. This study reported significant improvements in several self-evaluated 
outcomes including increases in circulation, strength, balance and muscle mass and 
reductions in pain, cramp and spasticity (self-reported measures with no statistical 
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testing were not included in Table 4). This is of concern given the use of an 
intervention group and no control; with clear risk of response bias and the potential 
for treatment effect [69]. The study provided resting and peak HR, however, this was 
poorly reported with resting and HRMAX values only assessed pre intervention, 
making interpretation difficult [39].  
 
Whilst the present review affirms the requirement for evaluating cardiorespiratory 
performance and FES cycle training in PwMS and EDSS ≥ 6.0, the lack of consistent 
measures of cardiorespiratory performance or other measures of CVD risk, mean it 
is difficult to draw conclusions regarding the effect on their cardiovascular health and 
CVD risk. Future research should accurately monitor cardiorespiratory performance 
and CVD risk factors before and after FES cycle training in PwMS and EDSS ≥ 6.0.  
 
Two interventions would not be replicable based on the information provided within 
the papers reviewed [40,45]. If the quality of evidence regarding FES cycling in 
PwMS is to improve, there is a clear requirement for statistically justifiable sample 
sizes and a consistency in intervention protocols/testing parameters to enable a 
future quantitative analysis. None of the papers included in this review had a follow 
up and so it remains unclear if there are any long lasting changes in outcome 
measures following a FES cycling intervention. In particular, this is important for 
PwMS based on the degenerative nature of the condition; where no change over 
time may represent a net clinical benefit. 
The use of functional tests was typically favoured in the present review in place of 
direct measures (Table 4). Whilst maintaining and/or improving function is of clear 
priority for PwMS when participating in exercise; it is important to note that the 
underlying mechanisms for conditioning and preservation of this function in PwMS 
and FES cycling are not understood at present. As such, isolating the underlying 
reasons for changes in functional tests and hence, the use of direct measures 
remains of important when evaluating FES cycling in PwMS. 
Most FES Cycling research has been in persons with complete SCI and the transfer 
of this exercise modality to PwMS is justifiable. However, future research must 
appreciate that PwMS will require different protocols which will need to be fully 
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reported. In particular, PwMS may still have some lower limb function making it more 
difficult to differentiate between the work provided by the individual (i.e. via central 
command) versus that provided by the stimulation. It would be beneficial if 
researchers clearly stated if participants were instructed and/or encouraged to cycle 
volitionally, and to what level/effort. For example, one paper in the present review 
instructed participants not to cycle volitionally, as the aim of their research was to 
isolate the effect of the electrical stimulation [39]. Volitional effort being encouraged 
or discouraged is not clearly reported across all the papers within this review. Where 
participants are asked to actively cycle, the variance in stimulation and WR across 
the session could provide insight regarding participant fatigability. 
 
5. Conclusion 
 
The current systematic review suggest that FES cycle training appears to be well 
tolerated in PwMS with mobility impairment. Findings suggest that FES cycle training 
may reduce CVD risk in some persons alongside trends suggesting reductions in 
spasticity post training. However, the low quality of the literature base precludes any 
definitive conclusions regarding the efficacy of FES cycle training in improving 
cardiovascular, musculoskeletal and functional outcomes in PwMS and higher EDSS 
scores. Future research should examine the use of FES cycle training in PwMS and 
mobility impairment using larger sample sizes, with correct statistical power, 
consistent cycle protocols and utilising direct objective measurable outcomes. 
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